PD-L1-Targeted and ROS-Responsive Nanoplatform for Simultaneous Chemotherapy and Dual-Modal Imaging of Treatment Response in Triple-Negative Breast Cancer
ACS Sensors · 2026
DOI: 10.1021/acssensors.6c03428 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Sensors, 2026. Verfasst von Jingjing Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200092, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Doxorubicin, Reactive Oxygen Species, B7-H1 Antigen. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai Leading Academic Discipline Project.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The evaluation of treatment response in triple-negative breast cancer (TNBC) still primarily relies on tumor size and ex vivo analyses, which provide very limited information on how tumors dynamically respond during therapy. In fact, oxidative stress rapidly emerges early after drug treatment, while PD-L1 reflects an adaptive signal associated with tumors. However, these treatment-associated features are commonly assessed using static detection methods, thereby limiting longitudinal in vivo evaluation. To address this, we developed a theranostic nanoprobe named RAPP, which integrates DOX delivery, ROS-responsive near-infrared fluorescence (NIRF) imaging, and PD-L1-targeted magnetic resonance imaging (MRI). In this system, the fluorescence signal serves to report early oxidative stress in real time, while PD-L1 targeting contributes to tumor-directed MRI, enabling longitudinal assessment of both signals in a 4T1 TNBC model. During treatment, RAPP produced distinct changes in fluorescence and MR signals across different experimental groups, indicating the complementarity of these two imaging modalities in evaluating tumor response. Furthermore, DOX-loaded RAPP effectively inhibited tumor growth without exhibiting significant systemic toxicity. By integrating drug delivery with dual-modal imaging, RAPP offers a practical strategy for assessing tumor response in TNBC during treatment, rather than only after treatment completion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200092, China.
- Faculty of Medical Imaging Technology, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai200025, China.
- Shanghai University of Sport , Shanghai200438, China.
ORCID-Profile: Defan Yao, Dengbin Wang
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Leading Academic Discipline Project
Zitieren
APA
Hu, J., Wang, C., Chen, Y., Zhu, C., Liu, A., Chen, D., Zhan, L., Yao, D., & Wang, D. (2026). PD-L1-Targeted and ROS-Responsive Nanoplatform for Simultaneous Chemotherapy and Dual-Modal Imaging of Treatment Response in Triple-Negative Breast Cancer. ACS Sensors. https://doi.org/10.1021/acssensors.6c03428
Vancouver
Hu J, Wang C, Chen Y, Zhu C, Liu A, Chen D, et al. PD-L1-Targeted and ROS-Responsive Nanoplatform for Simultaneous Chemotherapy and Dual-Modal Imaging of Treatment Response in Triple-Negative Breast Cancer. ACS Sensors. 2026. doi:10.1021/acssensors.6c03428
BibTeX
@article{Hu2026,
author = {Hu, Jingjing and Wang, Chunting and Chen, Yanhong and Zhu, Cuiying and Liu, Aoyu and Chen, Dian and Zhan, Ling and Yao, Defan and Wang, Dengbin},
title = {PD-L1-Targeted and ROS-Responsive Nanoplatform for Simultaneous Chemotherapy and Dual-Modal Imaging of Treatment Response in Triple-Negative Breast Cancer},
journal = {ACS Sensors},
year = {2026},
doi = {10.1021/acssensors.6c03428}
}
EUVIMED